ArticlemBio2023
A new tractable method for generating human alveolar macrophage-like cells
Open access · goldAbstract read
In one paragraph
Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- iPSC-based macrophage models reveal interferon-dependent control of RSV permissiveness and syncytia formation.Microbiology spectrum · 2026Article
- Dual human lung models reveal compartment-specific activity of anti-tuberculosis drugs and host-directed therapies.Microbiology spectrum · 2026Article
- Myeloid-derived alveolar-like macrophages are a tractable model to understand the role of ontogeny in alveolar macrophage functionbioRxiv : the preprint server for biology · 2026Article
- A high dimensionality approach reveals immunopathogenic responses driving severe pediatric acute respiratory distress syndrome.Nature communications · 2026Article
- Hippo pathway activation drives fibrogenic remodelling in influenza A virus-infected lung fibroblasts.ERJ open research · 2026Article
- Article
- Human iPSC-derived alveolar macrophages reveal macrophage subtype functions of itaconate in M. tuberculosis defense.JCI insight · 2026Article
- Lung organoids as a human system for Mycobacteria infection modeling and drug testing.The FEBS journal · 2026Review
- Article
- Autologous human iPSC-derived alveolus-on-chip reveals early pathological events ofScience advances · 2026Article
- Role of dual specificity phosphatase 1 in influencing inflammatory pathways in macrophages modulated byFrontiers in immunology · 2026Article
- NR4A nuclear receptor expression in human macrophages mediates apoptosis and controls Mycobacterium tuberculosis growth.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Human alveolar macrophage function is impaired in tuberculosis contacts with diabetes.EBioMedicine · 2025Article
- Pathogenicity and virulence ofVirulence · 2025Review
- Article
- Human alveolar macrophage response to Mycobacterium tuberculosis: immune characteristics underlying large inter-individual variability.Communications biology · 2025Article
- Synergy between pluripotent stem cell-derived macrophages and self-renewing macrophages: Envisioning a promising avenue for the modelling and cell therapy of infectious diseases.Cell proliferation · 2025Review
- Uncovering metabolic pathways in human alveolar macrophages in response to lipopolysaccharide.Clinical and experimental immunology · 2025Article
- Lung macrophages in pulmonary homeostasis and disease: from basic biology to clinical applications.Central-European journal of immunology · 2025Review
Corrections and comments
- Update of
Authors and funding
17 authors at 3 institutions in 1 country.
Susanta PahariHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.
Eusondia ArnettHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.
Jan SimperHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.
Abul AzadHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.
Israel Guerrero-ArgueroHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.
Chengjin YeHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.ORCID 0000-0002-1934-9494
Hao ZhangDepartment of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio , San Antonio, Texas, USA.
Hong CaiDepartment of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio , San Antonio, Texas, USA.
Yufeng WangDepartment of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio , San Antonio, Texas, USA.
Zhao LaiDepartment of Molecular Medicine, UT Health San Antonio , San Antonio, Texas, USA.
Natalie JarvisHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.
Miranda LumbrerasHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.
Diego Jose MaselliDivision of Pulmonary and Critical Care Medicine, UT Health Science Center , San Antonio, Texas, USA.
Jay PetersDivision of Pulmonary and Critical Care Medicine, UT Health Science Center , San Antonio, Texas, USA.
Jordi B TorrellesHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.
Luis Martinez-SobridoHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.ORCID 0000-0001-7084-0804
Larry S SchlesingerHost Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute , San Antonio, Texas, USA.
Texas Biomedical Research Institute · USTexas Center for Infectious Disease · USThe University of Texas Health Science Center at San Antonio · US
Funding
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1MInterdisciplinary NexGen TB research Advancement Center (IN-TRAC)P30AI168439 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Shannan Hall-Ursone · 2022 to 2026
$6.9MMacrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection- Diversity SupplementR01AI136831 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Eusondia A. Arnett, Larry S. Schlesinger · 2019 to 2026
$4.6MMechanism-based Targeting of the RNA Processing Machinery of SARS-CoV-2R01AI161363 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GUPTA, YOGESH K · 2021 to 2025
$3.2MThe origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5MAdvancing Cancer Research Through Next Generation Sequencing at Mays Cancer Center of UT Health San AntonioR50CA265339 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Zhao Lai · 2022 to 2026
$957kHigh Throughput DNA Sequencer: Illumina HiSeq 3000 SequencerS10OD021805 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2016 to 2016
$600kIllumina NovaSeq 6000 Sequencing SystemS10OD030311 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2021 to 2021
$600kBD FACSymphonyS10OD028653 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI TURNER, JOANNE · 2020 to 2020
$463kNCI NIH HHS P30 CA054174NCI NIH HHS R50 CA265339NIAID NIH HHS P30 AI168439NIAID NIH HHS R01 AI136831NIAID NIH HHS R01 AI161175NIAID NIH HHS R01 AI161363NIH HHS S10 OD021805NIH HHS S10 OD028653NIH HHS S10 OD030311
Abstract
Alveolar macrophages (AMs) are unique lung resident cells that contact airborne pathogens and environmental particulates. The contribution of human AMs (HAMs) to pulmonary diseases remains poorly understood due to the difficulty in accessing them from human donors and their rapid phenotypic change during
Indexed as
COVID-19Leukemia, Myeloid, AcutePneumoniaAnimalsCattleHumansLungMacrophages, AlveolarSARS-CoV-2alveolar macrophage-like (AML) cellshuman alveolar macrophageslung cytokinesMycobacterium tuberculosisoxidative phosphorylationSARS-CoV-2surfactant
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.